FDA approves expanded use of Janssen's Darzalex for multiple myeloma patients

Horsham, Pa.-based Janssen Biotech, a subsidiary of Johnson & Johnson, received Food and Drug Administration approval for an expanded use of its immunotherapy drug Darzalex.

Darzalex can now be used in combination with two standard of care regimens —lenalidomide and dexamethasone, or bortezomib and dexamethasone — for the treatment of patients with multiple myeloma who have received at least one prior therapy, according to a company news release.

The FDA first approved the drug in November 2015 and the medication earned breakthrough therapy designation for the new indication in July 2016.

More articles on supply chain:

Novo Nordisk, Sanofi to battle for sales with new combination diabetes drugs: 4 takeaways
Sanofi earns FDA approval for type 2 diabetes treatment
FDA approves Novo Nordisk's new combination therapy for type 2 diabetes

Copyright © 2023 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars